Elebsiran

Drug identity checked against registry records

Also recorded as VIR-2218

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811VIRPhase 2Active not recruiting2029-03Estimated
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550VIRPhase 3Active not recruiting2026-12Estimated
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionNCT06903338VIRPhase 3Active not recruiting2026-09-30Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.